Ruiming New Drug
At a glance
- Status
- Operational
- Open positions
- None listed
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Apr 2022 | $14M | $55M | Jinding Capital · China Resources Zhengda Life Science | ↗ |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Ruiming New Drug in its local ecosystem
The Ruiming New Drug office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Jinding Capital- CSChina Resources Zhengda Life Science
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ruiming New Drug on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ruiming New Drug’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.